Boston Partner Roger Lane was quoted in a July 9, 2013 Law360 article titled “Pain Now or Later? Thermo Fisher Tastes Earnout Bitters.” The article discusses how earnouts often result in infighting rather than bridging the gap between what sellers want and what buyers are willing to pay for unproven assets-something Thermo Fisher Scientific Inc. is finding out. Mr. Lane, a member of Foley’s Emerging Technologies Industry Team, was quoted saying, “Most buyers are reluctant to make guarantees about budgets or staffing levels. Often a seller’s best hope is a negative covenant, where the buyer promises not to do anything to undermine the seller’s efforts.” Mr. Lane also stated, “You can’t anticipate everything. You handicap the deal the best you can, and you live with it … especially when the alternative is that there is no deal.” But “at the end of the day, terms like that mean different things to different people, in light of circumstances that may have changed,” Mr. Lane said. “That’s most often what the litigation comes down to – interpreting the terms you spend all that time hammering out.”
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”